NCT05106127 2025-12-08Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus PemEvergreen Therapeutics, Inc.Phase 2 Not yet recruiting28 enrolled
NCT06046274 2024-04-30GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerGenmabPhase 2 Withdrawn